2020
DOI: 10.1111/dth.14282
View full text
|
Sign up to set email alerts
|
Share

Abstract: Dupilumab is a monoclonal antibody which selectively inhibits the α-subunit of IL-4 and IL-13, which are involved in the pathogenesis of atopic dermatitis. It is the only targeted systemic treatment FDA approved to treat moderate-to-severe atopic dermatitis in adolescents and adults. 1 As systemic treatment for severe atopic dermatitis in children under 6 years of age is lacking, off-label use of dupilumab is

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals